FAIRFIELD, Conn., May 6, 2014 /PRNewswire/ -- Competitive
Technologies, Inc., (CTI), the pain mitigation company, will
host a private engagement for top opinion leaders in oncology at
the Hyatt Regency McCormick Place on June 1,
2014 during the 50th Annual American Society of
Clinical Oncology (ASCO) in Chicago,
IL.
At the private engagement, there will be a morning panel
discussion on the treatment of chemotherapy-induced peripheral
neuropathy (CIPN) using Calmare Pain Device Therapy. The panel will
consist of Dr. Thomas J. Smith from
the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Medicine and Dr. Charles L.
Loprinzi, Regis Professor of Breast Cancer Research,
Division of Medical Oncology at the Mayo Clinic.
CTI will exhibit and feature their signature device, the Calmare
Pain Device, at Booth 5072 at the McCormick Center during ASCO.
"ASCO 50th annual meeting is the perfect venue to
introduce Calmare to the world's top opinion leaders," commented
CTI President & CEO Conrad Mir.
"We feel Calmare therapy may be the alternative therapy that
patients, plagued with chronic pain, need in order to return to a
pain-free lifestyle. As a medical device Company furthering such an
innovative product, it is important that the medical community is
made aware of this non-invasive approach that may revolutionize the
way pain is managed."
About the Chemotherapy Induced Peripheral Neuropathy
CIPN is the damage done to the peripheral nervous system – the
system that transmits information between the central nervous
system and the rest of the body. It is caused by a host of
chemotherapeutic agents. Symptoms include numbness, tingling or
burning sensations, and often begin in the fingertips or toes and
may progress. An estimated 30 to 40 percent of cancer patients
treated with chemotherapy experience these symptoms.
About the Private Engagement
Management is hosting an invite-only event for a select group of
the world's top medical leaders. Formal invitations have been sent.
For further information, please email CTI headquarters:
ASCO@competitivetech.net on or before Friday, May 23, 2014.
About the Company
Competitive Technologies Inc., the pain mitigation company,
develops and commercializes innovative wound and pain management
products and technologies. CTI holds the 510k clearance on its
flagship product, the non-invasive Calmare® Pain Therapy
Device, which grants it an exclusive right to sell, market,
research and develop the medical device. The Company is the
exclusive licensed global distributor of Calmare.
Forward-Looking Statement
Certain statements contained in this press release are
forward-looking statements that involve risks and uncertainties.
The statements contained herein that are not purely historical are
forward looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
statements deal with the Company's current plans, intentions,
beliefs and expectations and statements of future economic
performance. Forward-looking statements involve known and
unknown risks and uncertainties that may cause the Company's actual
results in future periods to differ materially from what is
currently anticipated. Factors that could cause or contribute to
such differences include those discussed from time to time in
reports filed by the Company with the Securities and Exchange
Commission. The Company cannot guarantee its future results, levels
of activity, performance or achievements.
Contacts:
|
|
Competitive
Technologies,
Inc.
|
JV Public
Relations
|
Conrad
Mir
|
Janet
Vasquez
|
President and
CEO
|
Managing
Director
|
cmir@competitivetech.net
|
jvasquez@jvprny.com
|
973.798.8882
|
212.645.5498
|
Calmare®: www.calmarett.com
Visit us: www.competitivetech.net | Follow us: Facebook.com
Logo -
http://photos.prnewswire.com/prnh/20131015/NY97852LOGO
SOURCE Competitive Technologies, Inc.